Introduction
============

Lung cancer is the leading cause of cancer-related deaths in men and the second leading cause of cancer death in women worldwide and presents a serious problem to global health ([@b1-ol-0-0-9044]). It was estimated that 1.8 million new lung cancer cases and 1.6 million lung cancer related deaths occurred in 2012 worldwide, accounting for approximately 19% of all cancer deaths ([@b2-ol-0-0-9044]). In recent decades, despite of great research effort in diagnosis and treatment for lung cancer, progress in the treatment is still slow ([@b3-ol-0-0-9044]). Non-small cell lung cancer (NSCLC) is the major lung cancer, accounts for approximately 85% of lung cancer. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the major two pathological subtypes of NSCLC and in many ways they are different, such as originate, biological patterns and molecular characteristics ([@b4-ol-0-0-9044]--[@b6-ol-0-0-9044]). Related studies on NSCLC should be analyzed separately according to histological type.

Interleukin-6 (IL-6) signaling through IL-6 receptor (IL-6R) regulates cell growth and differentiation and plays an important role in the immune response ([@b7-ol-0-0-9044]). This signaling pathway can also promote tumor growth which has both pro-inflammatory and anti-inflammatory effect ([@b8-ol-0-0-9044]). Evidence has shown that the IL-6 signaling pathway contribute to the pathogenesis of NSCLC ([@b9-ol-0-0-9044]). Several studies have revealed the role of IL-6 in NSCLC and suggested that it promotes tumor growth and survival ([@b10-ol-0-0-9044]--[@b12-ol-0-0-9044]). Increased expression of IL-6R in human LUSC-derived cells (HARA-B) has been shown *in vitro* ([@b13-ol-0-0-9044]) and in a murine model of brain metastasis ([@b14-ol-0-0-9044]). Tocilizumab is an anti-IL-6R antibody, upon application, the stimulated growth of HARA-B cells was significantly inhibited and when it was injected to the animal model, the volume of metastatic focus was significantly smaller ([@b14-ol-0-0-9044]). Studies also have demonstrated that blockade of IL-6R can significantly suppress the proliferation of NSCLC cell and reduce the mRNA levels of IL-6R ([@b15-ol-0-0-9044],[@b16-ol-0-0-9044]). Meanwhile, tocilizumab also seems to be effective for lung cancer cachexia ([@b17-ol-0-0-9044],[@b18-ol-0-0-9044]). However, there was no study investigating the prognostic effect of IL-6R on lung cancer, which is addressed by our current study.

Materials and methods
=====================

### Search strategy

We searched public databases such as The Cancer Genome Atlas (TCGA) and Gene Expression Ominibus (GEO database; last update by July 03, 2017) using the keywords 'Lung cancer'. The search strategy is designed as follows: The study type was set as 'expression profiling by array. The entry type was set as 'datasets'. The sample size of all selected datasets should be greater or equal to 100. The organism was homo sapiens. Database searching was carried out by two researchers independently.

### Data extraction and quality assessment

Data from all eligible datasets were abstracted independently by two authors, using information recorded as follows: First author\'s surname, publication year, origin of population, sample number, tumor stage, follow-up period and clinic outcome. We separate those microarray datasets into LUAD and LUSC. HRs and 95% CIs were evaluated by Cox\'s proportional hazards model.

The quality of all eligible studies was assessed according to the Newcastle-Ottawa Quality Assessment Scale (NOS) by two researchers independently ([@b19-ol-0-0-9044]). The quality scores span from 0 to 9, and higher the score is, higher the quality is.

### Statistical analysis

For those public microarray data, gene expression was represented by metric variables. We use Cutoff Finder (<http://molpath.charite.de/cutoff>) to determine a cutoff point and stratify patients into two groups ([@b20-ol-0-0-9044]). The range of IL-6R mRNA values for each data and the corresponding cutoff values were listed in [Table I](#tI-ol-0-0-9044){ref-type="table"}. HRs and 95% CIs were calculated to measure the effective prognostic value of expression of IL-6R mRNA in LUAD and LUSC patients. Pooled HRs were carried out using STATA software package (version 12.0; Stata Corp LP, College Station, TX, USA). All P-values were obtained upon two tailed analysis.

In The Cancer Genome Atlas (TCGA) lung adenocarcinoma dataset and TCGA lung squamous cell carcinoma dataset, there were gene expression data in both tumor and normal tissues. We used paired test to compare the differences in IL-6R mRNA expression between tumor and adjacent normal tissues.

For each dataset, we calculated the correlation coefficient between IL-6R and the remaining genes, and then matched the coefficients in all datasets. Genes with absolute correlation coefficient which were greater than 0.4 in half or more publications were extracted. 193 genes in LUAD and 101 genes in LUSC were included in subsequent analysis ([Table II](#tII-ol-0-0-9044){ref-type="table"}).

Functional enrichment analysis of genes whose expressions are significantly correlated that of IL-6R was performed to allow the identification of biological processes or functions associated with IL-6R expression. In this study, the Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to analyze gene enrichment and pathway analysis to explore the biological processes of gene enrichment (<https://david.ncifcrf.gov/summary.jsp>).

Results
=======

### Study characteristics

A total of 7 related studies were identified from the GEO database (GSE14814 ([@b21-ol-0-0-9044]), GSE30219 ([@b22-ol-0-0-9044]), GSE37745 ([@b23-ol-0-0-9044]), GSE42127 ([@b24-ol-0-0-9044]), GSE50081 ([@b25-ol-0-0-9044]), GSE68465 ([@b26-ol-0-0-9044]), GSE68571 ([@b27-ol-0-0-9044])). Including TCGA lung adenocarcinoma and TCGA lung squamous cell carcinoma datasets, 9 datasets were included in our analysis. In the initial screening, a total of 779 potentially relevant datasets from the GEO database were selected for keyword retrieval. A total of 680 datasets were retrieved after screening sample size and organism. After examination of summary and the clinic outcome of those data, a total of 7 microarray datasets from the GEO database that met the inclusion criteria were included in the present study. Finally, 8 datasets and 6 datasets for adenocarcinoma and squamous cell carcinoma respectively were further analyzed ([Fig. 1](#f1-ol-0-0-9044){ref-type="fig"}). [Table III](#tIII-ol-0-0-9044){ref-type="table"} showed the baseline characteristics of all included studies. Date of 1,536 LUAD and 739 LUSC patients from Canada, France, UK and USA were included in this analysis.

A quality assessment of the eligible datasets included in this meta-analysis has been performed according to Newcastle-Ottawa Quality Assessment Scale (NOS). The quality score span was from 6 to 9 and the mean score was 7.63 for LUAD and the quality score span was from 6 to 8 and the mean score was 7.33 for LUSC. The impact factors of the journals where the studies were published were of high caliber ([Table III](#tIII-ol-0-0-9044){ref-type="table"}). Thus, all of those studies were included in following analysis.

### Overall survival

Univariate analysis and multivariate analysis were respectively carried out for each dataset. P-values, HRs and 95% CIs of IL-6R mRNA in each article for LUAD and LUSC were shown in [Table IV](#tIV-ol-0-0-9044){ref-type="table"} and [Figs. 2](#f2-ol-0-0-9044){ref-type="fig"} and [3](#f3-ol-0-0-9044){ref-type="fig"}.

For LUAD, there was no obvious statistical heterogeneity in all of those datasets both in univariate survival analysis and multivariate survival analysis (I^2^=0.0%, P=0.806; I^2^=0.0%, P=0.742), a fixed-effects model was used to calculate the pool HRs. Our analysis demonstrated that a higher expression of IL-6R mRNA was significantly associated with better overall survival (OS) (pooled HR=0.50; 95% CI: 0.33--0.68 in univariate analysis; pooled HR=0.50; 95% CI: 0.35--0.73 in multivariate analysis). The forest plots of study-specific HRs for OS were presented in [Fig. 4](#f4-ol-0-0-9044){ref-type="fig"}.

For LUSC, we still used a fixed-effects model to pool the HRs (I^2^=29.3%, P=0.215; I^2^=36.5%, P=0.217). Interestingly, there was no association between IL-6 mRNA and OS in patients with LUSC (pooled HR=1.59; 95% CI: 0.98--2.59 in univariate analysis; pooled HR=1.64; 95% CI: 0.98--2.75 in multivariate analysis). The forest plots of study-specific HRs for OS were presented in [Fig. 5](#f5-ol-0-0-9044){ref-type="fig"}.

### Correlation between IL-6 and IL-6R, IL-6R and IL-6ST

The IL-6 receptor is a protein complex consisting of an alpha chain, IL-6R, and IL-6 signal transducer (IL-6ST). Relationship between the mRNA expression of IL-6 and IL-6R, and between IL-6R and IL-6ST were all analyzed in those datasets. We then performed a meta-analysis based on Fisher\'s z transformation. Interestingly, IL-6 and IL-6R were negatively correlated in LUAD (pooled r=−0.199, P\<0.001), while they were positively correlated in LUSC (pooled r=0.288, P=0.001). The correlation coefficient between IL-6R and IL-6ST in LUAD was similar with correlation coefficient in LUSC (pooled r=0.331, P\<0.001 in LUAD and pooled r=0.334, P\<0.001 in LUSC; [Table V](#tV-ol-0-0-9044){ref-type="table"}).

### IL-6R mRNA expression in tumor tissues and adjusted normal tissues

TCGA lung adenocarcinoma and TCGA lung squamous cell carcinoma datasets contains gene expression data both in tumor tissues and normal tissues. There were 57 and 51 pairs in LUAD and LUSC. In both two types of lung cancer, IL-6R mRNA expression level in tumor tissues was less than normal tissues (P\<0.001; [Fig. 6](#f6-ol-0-0-9044){ref-type="fig"}).

### Biological processes and pathway analysis

Functional enrichment analysis was performed on IL-6R and the most related genes (all those genes were shown in [Table II](#tII-ol-0-0-9044){ref-type="table"}). [Table VI](#tVI-ol-0-0-9044){ref-type="table"} lists the top five biological processes and pathways enriched in IL-6R correlated genes in LUAD. One of the most significant biological processes is cell division (GO:0051301, P=4.038E-20). Results also showed that those genes enriched in mitotic division. GO:0007067, mitotic nuclear division, GO:0007059, chromosome segregation, GO:0000070, mitotic sister chromatid segregation and GO:0045143, homologous chromosome segregation.

The most important pathway in LUAD is cell cycle (bta04110, P=8.584E-15). As with the results of biological processes, pathway analysis also shows that these genes are involved in cell division, eg. oocyte meiosis (bta04114, P=2.573E-07), progesterone-mediated oocyte maturation (bta04914, P=3.845E-06). The other two important pathways are p53 signaling pathway (bta04115, P\<0.001) and HTLV-I infection (bta05166, P=0.008).

[Table VII](#tVII-ol-0-0-9044){ref-type="table"} lists the top five biological processes and pathways enriched in LUSC. The most significant biological processes are regulation of cell proliferation (GO:0042127, P=0.001) and positive regulation of osteoclast differentiation (GO:0045672, P=0.003). Result also showed that those genes are involved in immune response (GO:0006955, P=0.003). The other two biological processes are trans-membrane receptor protein tyrosine kinase signaling pathway (GO:0007169, P=0.006) and integrin-mediated signaling pathway (GO:0007229, P=0.006).

The most important pathway in LUSC is natural killer cell mediated cytotoxicity (ptr04650, P\<0.001). And the others are osteoclast differentiation (ptr04380, P=0.002), platelet activation (ptr04611, P=0.011), cytokine-cytokine receptor interaction (ptr04060, P=0.015) and HTLV-I infection (ptr05166, P=0.028).

Discussion
==========

Lung cancer is a serious threat to public health in the world. Cytokines play important roles in tumorigenesis as well as immune surveillance of lung cancer. LUAD and LUSC are two main pathological subtypes of NSCLC. To study the association of various cytokines and their receptors with clinical parameters of NSCLC is an important step for further mechanistic investigations and provides insight into new therapeutic targets. Our study revealed that higher expression levels of IL-6R mRNA in tumor tissues were positively associated with better overall survival in LUAD. These data suggest an antitumoral role of IL-6R signaling.

Recent works have demonstrated that IL-6 signaling pathway plays an important role in the immune response ([@b28-ol-0-0-9044]). Several studies have demonstrated the pro-tumor effect of IL-6 in NSCLC. Our study revealed a predictive value of IL-6R mRNA expression in LUAD. It suggested that higher IL-6R mRNA was associated with better survival. However, the prognostic value of IL-6R was not shown in LUSC. It is speculated that LUAD and LUSC arise from distinct cells based on the histopathological appearance and gene expression signatures. It is generally accepted that LUAD originates mainly from alveolar epithelial cells and LUSC is possibly derived from basal cells ([@b29-ol-0-0-9044],[@b30-ol-0-0-9044]). LUAD and LUSC undergo distinct developmental processes. Several articles also have showed different result between LUAD and LUSC. One study showed that an increased expression of the embryonic stem cells gene set was associated with overall survival in LUAD. However, there was no correlation in LUSC ([@b31-ol-0-0-9044]). Meanwhile, other study found that the expression levels of PTN1 genes were associated with survival in LUAD but not LUSC ([@b32-ol-0-0-9044]). The different results may mainly due to its different cellular origins, developmental stages and tumor microenvironment.

In LUAD, enrichment analysis of IL-6R and its most relevant genes showed that the most significant biological processes were cell division and mitotic division. That means those genes mainly involved in cell cycle progression in LUAD. While in LUSC, the most significant biological processes were regulation of cell proliferation and several signaling pathway. Pathways analysis revealed that those genes were involved in natural killer cell mediated cytotoxicity and platelet activation, meaning that they were mostly involved in tumor angiogenesis, invasion and metastasis. Genes that mostly related with IL-6R and the most significant biological processes were all different in LUAD and LUSC. That means the tumor microenvironment in both cancers were discriminate. This prompts us that studies on LUAD and LUSC should be analyzed separately.

In our report, although there was no statistical significance between IL-6R mRNA expression and OS in LUSC, the lower 95% CI limit of HR (0.98) were very close to 1, showing a trend that IL-6R may be a risk factor for LUSC. Considering the small sample size in each study, further investigations with a larger scale of samples are needed to confirm this result.

IL-6R is a part of the receptor for IL-6 which binds to IL-6 with low affinity, but does not transduce a signal ([@b33-ol-0-0-9044]). IL-6ST is necessary for this signal activation. Correlation analysis showed that IL-6 and IL-6R were negative correlated in LUAD while they were positive correlated in LUSC, indicating that the higher the expression of IL-6R, the lesser the expression of IL-6 in LUAD and the higher the expression of IL-6 in LUSC. And the pooled correlation coefficient of IL-6R and IL-6ST were positive both in LUAD and LUSC. However, Brooks *et al* have found that IL-6R protein displayed a positive correlation with IL-6 in LUAD ([@b34-ol-0-0-9044]). The correlation coefficient of IL-6 and IL-6R in LUAD and LUSC were −0.199 and 0.288, respectively. Both of them were less than 0.3, showing a weak correlation. In our report, the correlation between IL-6 and IL-6R was calculated based on public datasets, showing a possible phenomenon. The possible biological process or interaction between these cytokines should be verified at a tissue, cellular or molecular level by subsequent experimental verification.

In TCGA dataset, we found that IL-6R mRNA expression level in tumor tissues was less than normal tissues in both LUAD and LUSC. Balabko *et al* have demonstrated the same trend, and they also found that IL-6R mRNA was found significantly induced in the tumoural region of LUAD as compared to LUSC ([@b35-ol-0-0-9044]). STAT3, a transcription factor downstream of IL-6R, has also been found increased and phosphorylated in LUAD while there was no phosphorylation in LUSC ([@b35-ol-0-0-9044]). Considering the different effect of IL-6R mRNA in LUAD and LUSC, we deduce that the expression level of IL-6R mRNA can affect the expression level of IL-6 and the activation of downstream pathways and can affect the most important biological processes it involved in.

However, some details need to be further refined. Firstly, this study included only 8 eligible datasets for LUAD and 6 studies for LUSC, which resulted in relatively insufficiency data in the subgroup analyses. Secondly, sample size of LUSC in each study was smaller than LUAD, further articles with a larger scale of samples are needed to confirm the result. Thirdly, these results were calculated based on public datasets and these results should be verified using cells or tumor samples.

In conclusion, our results showed that mRNA levels of IL-6R in LUAD was associated with better prognosis and can potentially be used as a prognostic marker for this cancer. While in LUSC, although there was no statistically significance between IL-6R mRNA and OS in LUSC, taking the small sample size of each dataset, the results should be regarded cautiously. Further prospective studies available of pivotal parameters are needed to verify the prognosis value of IL-6R in LUAD and LUSC patients.
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###### 

Cut-off value of IL-6R.

  Datasets     Minimum   P~25~     Median    Mean      P~75~     Maximum    Cut-off value
  ------------ --------- --------- --------- --------- --------- ---------- ---------------
  LUAD                                                                      
    GSE14814   4.211     4.779     5.027     5.134     5.394     6.611      4.607
    GSE30219   5.127     6.343     6.908     7.019     7.686     9.247      7.648
    GSE37745   3.970     7.232     7.698     7.697     8.272     10.200     7.789
    GSE42127   3.670     4.475     4.930     4.945     5.405     7.680      5.515
    GSE50081   5.049     7.281     7.809     7.823     8.405     10.049     7.675
    GSE68465   31.955    246.235   361.102   437.587   543.700   1940.570   393.500
    GSE68571   −41.850   17.188    52.725    69.762    101.213   297.650    44.020
    TCGA       4.360     8.364     9.037     8.970     9.274     11.608     9.125
  LUSC                                                                      
    GSE14814   4.324     4.644     4.912     4.909     5.076     5.871      5.072
    GSE30219   4.232     5.430     6.004     5.946     6.453     7.988      5.741
    GSE37745   4.523     6.395     6.992     6.851     7.458     8.770      7.637
    GSE42127   2.830     4.100     4.390     4.456     4.730     6.260      4.115
    GSE50081   5.475     6.681     7.144     7.125     7.421     9.009      6.678
    TCGA       3.751     7.456     8.286     8.171     8.879     10.982     9.134

IL, interleukin; TCGA, The Cancer Genome Atlas; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

###### 

Gene list in LUAD and LUSC.

  Cancer   Gene names
  -------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LUAD     ABCC3, ADCY9, AKAP13, ALDH2, ALDH5A1, ALOX15B, APLP2, APOH, AQP3, ARHGAP31, ASF1B, ASPM, ATP13A4, AURKB, BFAR, BIRC5, BUB1, BUB1B, C16orf89, C1orf116, C5orf46, CC2, CCNB1, CCNB2, CCND3, CD302, CD81, CDC20, CDC25A, CDC25C, CDC45, CDC6, CDCA2, CDCA3, CDCA5, CDCA8, CDK1, CDKL2, CDKN3, CDT1, CEBPA, CENPM, CENPN, CENPW, CEP55, CHEK1, CISH, CITED2, CKS2, CLIC3, CLIC5, COL4A3, COL4A4, CPM, CRY2, CTDSPL, CTSH, CYP4B1, DEPDC1, DEPDC1B, DJC9, DLC1, DLGAP5, DYNLL1, ECHDC2, ESPL1, EVPL, EXO1, FAM184A, FAM64A, FAM83D, FANCG, FANCI, FBP1, FBXO5, FCGRT, FEN1, FMO5, FNIP2, FOLR1, FOXM1, GALNT11, GAPDH, GGT1, GGTLC1, GINS1, GPD1L, GPR116, GTSE1, H2AFX, HIP1, HJURP, HLF, HNF1B, ICAM4, ICAM5, IL6R, INMT, KIAA0101, KIF11, KIF18B, KIF20A, KIF23, KIF2C, KIF4A, KIFC1, KNTC1, LOC101930052, LRRK2, MAD2L1, MALL, MAMDC2, MELK, MGLL, MGRN1, MIR3658, MIR6883, MKI67, MLLT11, MTHFD2, MUC1, NBEAL1, NCAPG, NCAPH, NDC80, NEK2, NPC2, NRM, NUF2, NUSAP1, OCLN, OIP5, PARM1, PARPBP, PBK, PC, PCDP1, PEBP4, PI4KB, PLA2G1B, PLK1, PLLP, PMVK, POLE2, PON3, PRC1, PRR15L, PSA, PSRC1, PTS, PTTG1, RAD51AP1, RAD54L, RFC4, RRM2, RSE1, RSEH2A, SELENBP1, SFTA1P, SFTPD, SKA1, SKA3, SLC22A3, SLC34A2, SLC41A1, SNX30, SPAG5, SPAG9, SPC25, ST3GAL5, STAT6, STIL, SUSD2, SYNE1, TLR2, TLR5, TMEM163, TMEM243, TMPRSS2, TPX2, TRIP13, TROAP, TTK, TUBA1C, TUBB, TYMS, UBE2C, UBE2T, UHRF1, USP13, ZBTB4, ZNF385B, ZWINT
  LUSC     ADAP2, ADCY9, ANXA11, APOBR, ARHGEF3, BTK, BUB1B, C1RL, CCR1, CD37, CD4, CD52, CD93, CD97, CEBPD, COQ3, CORO1A, CRTAP, CSE1L, CTSH, DENND2D, DHX9, DOK2, DUT, ECT2, EPAS1, EZH2, FBXO5, FGR, FHOD1, FOS, GIMAP6, HDAC2, HLA-DPB1, HLA-DQB1, IER2, IFITM1, IL2RB, IL6R, ITGAL, JUNB, KIF15, KLF10, LCP2, LRP10, LSM4, LST1, MAST3, MCM6, MOSPD1, MSH6, MSN, MVP, MYO1F, P2RY13, PAGR1, PDCD5, PDE4A, PLEKHO2, PLIN3, POLA1, PPP1CC, PPP1R16B, PRKCB, PTAFR, PTK2B, PTPN6, RAB27A, RAB31, RAD51AP1, RAD54B, RCN2, RHOG, RPL22, S1PR1, SASH3, SIGLEC1, SLA, SLCO2B1, THEMIS2, TMPO, TNFRSF1A, TNFRSF1B, TPP1, TRANK1, TRPV2, TYROBP, VASP, VWF, ZFYVE26, ARHGAP30, ARHGAP9, C1orf162, CARD6, CXCL16, GIMAP1, LOC100129034, LRRCC1, SARNP, TNFAIP8L2, ZNF664

LUAD, adenocarcinoma; LUSC, squamous cell carcinoma.

###### 

Baseline characteristics of microarray data.

  Datasets   Author        Year   Country   Median duration, months (range)   Sample size   Stage                         Outcome measures   Quality score   Journal                          IF       (Refs.)
  ---------- ------------- ------ --------- --------------------------------- ------------- ----------------------------- ------------------ --------------- -------------------------------- -------- ----------------------
  LUAD                                                                                                                                                                                                 
  GSE14814   Zhu CQ        2010   Canada    60.84 (0.36--109.08)              70            I/II (41/29)                  OS                 8               Journal of clinical oncology     24.008   ([@b21-ol-0-0-9044])
  GSE30219   Rousseaux S   2013   France    68.00 (0--221)                    85            NR                            OS                 7               Science translational medicine   16.796   ([@b22-ol-0-0-9044])
  GSE37745   Botling J     2013   UK        47.80 (0.20--187.79)              106           I/II/III/IV (70/19/13/4)      OS                 8               Clinical cancer research         9.619    ([@b23-ol-0-0-9044])
  GSE42127   Tang H        2013   USA       45.60 (0--132)                    133           I/II/III/IV (89/22/20/1)      OS                 7               Clinical cancer research         9.619    ([@b24-ol-0-0-9044])
  GSE50081   Der SD        2014   Canada    52.44 (1.08--130.56)              129           I/II (93/36)                  OS                 6               Journal of thoracic oncology     6.595    ([@b25-ol-0-0-9044])
  GSE68465   Shedden K     2008   USA       47.00 (0.03--204.00)              442           NR                            OS                 9               Nature medicine                  29.886   ([@b26-ol-0-0-9044])
  GSE68571   Beer DG       2002   USA       29.50 (1.50--110.60)              86            I/III (67/19)                 OS                 8               Nature medicine                  29.886   ([@b27-ol-0-0-9044])
  TCGA       TCGA          2015   USA       15.35 (0.00--223.96)              485           I/II/III/IV (262/118/79/25)   OS                 8               --                               --       
  LUSC                                                                                                                                                                                                 
  GSE14814   Zhu CQ        2010   Canada    73.56 (8.28--111.48)              52            I/II (25/27)                  OS                 8               Journal of clinical oncology     24.008   ([@b21-ol-0-0-9044])
  GSE30219   Rousseaux S   2013   France    59.00 (1--256)                    61            NR                            OS                 7               Science translational medicine   16.796   ([@b22-ol-0-0-9044])
  GSE37745   Botling J     2013   UK        36.36 (0.20--179.80)              66            I/II/III (40/15/11)           OS                 8               Clinical cancer research         9.619    ([@b23-ol-0-0-9044])
  GSE42127   Tang H        2013   USA       48.00 (0.00--128.40)              43            I/II/III (23/10/10)           OS                 7               Clinical cancer research         9.619    ([@b24-ol-0-0-9044])
  GSE50081   Der SD        2014   Canada    62.16 (5.76--144.48)              43            I/II (27/16)                  OS                 6               Journal of thoracic oncology     6.595    ([@b25-ol-0-0-9044])
  TCGA       TCGA          2015   USA       17.27 (0.03--174.08)              474           I/II/III/IV (232148/84/7)     OS                 8               --                               --       

LUAD, adenocarcinoma; LUSC, squamous cell carcinoma; TCGA, The Cancer Genome Atlas; NR, not report; OS, overall survival; IF, impact factor.

###### 

HR of interleukin-6R mRNA for OS.

                                                             Univariate analysis   Multivariate analysis                                                   
  ---------------------------------------------------------- --------------------- ----------------------- -------- ------------- ------- ------- -------- --------------
  LUAD                                                                                                                                                     
    GSE14814^[c](#tfn7-ol-0-0-9044){ref-type="table-fn"}^    0.201                 0.092                   0.443    **\<0.001**   0.190   0.076   0.474    **\<0.001**
    GSE30219^[d](#tfn8-ol-0-0-9044){ref-type="table-fn"}^    0.237                 0.093                   0.603    **0.003**     0.215   0.081   0.566    **0.002**
    GSE37745^[c](#tfn7-ol-0-0-9044){ref-type="table-fn"}^    0.659                 0.416                   1.044    0.076         0.589   0.303   1.147    0.120
    GSE42127^[c](#tfn7-ol-0-0-9044){ref-type="table-fn"}^    0.559                 0.267                   1.168    0.122         0.693   0.319   1.505    0.354
    GSE50081^[e](#tfn9-ol-0-0-9044){ref-type="table-fn"}^    0.493                 0.287                   0.846    **0.010**     0.656   0.370   1.163    0.149
    GSE68465^[f](#tfn10-ol-0-0-9044){ref-type="table-fn"}^   0.492                 0.375                   0.646    **\<0.001**   0.566   0.426   0.752    **\<0.0001**
    GSE68571^[g](#tfn11-ol-0-0-9044){ref-type="table-fn"}^   0.492                 0.217                   1.117    0.089         0.602   0.256   1.418    0.246
    TCGA^[h](#tfn12-ol-0-0-9044){ref-type="table-fn"}^       0.617                 0.436                   0.873    **0.006**     0.515   0.344   0.772    **0.001**
  LUSC                                                                                                                                                     
    GSE14814^[i](#tfn13-ol-0-0-9044){ref-type="table-fn"}^   1.701                 0.669                   4.323    0.264         1.589   0.597   4.227    0.354
    GSE30219^[d](#tfn8-ol-0-0-9044){ref-type="table-fn"}^    1.440                 0.748                   2.775    0.275         1.559   0.797   3.050    0.194
    GSE37745^[c](#tfn7-ol-0-0-9044){ref-type="table-fn"}^    2.599                 1.344                   5.029    **0.005**     4.071   1.436   11.537   **0.008**
    GSE42127^[c](#tfn7-ol-0-0-9044){ref-type="table-fn"}^    9.906                 1.321                   74.297   **0.026**     8.577   1.084   67.868   **0.042**
    GSE50081^[j](#tfn14-ol-0-0-9044){ref-type="table-fn"}^   0.442                 0.149                   1.312    0.141         0.387   0.119   1.257    0.114
    TCGA^[h](#tfn12-ol-0-0-9044){ref-type="table-fn"}^       1.375                 0.954                   1.981    0.088         1.308   0.899   1.903    0.161

P\<0.05 indicated in bold.

Data were compared using Univaruate Cox\'s proportional hazards model

data were compared using multivariate Cox\'s proportional hazards model. Multivariate analysis adjusted variables

age, sex, stage, post-treatment

age, sex, T, N

age, sex, stage, T, N

age, sex, T, N, adjuvant-chemotherapy, adjuvant-radio-therapy

age, sex, tumor size, stage

age, sex, stage, T, N, M

age, stage, post-treatment

age, sex, stage, T. HR, hazard ratio; LCI, lower 95% confidence interval; UCI, upper 95% confidence interval; TCGA, The Cancer Genome Atlas; LUAD, adenocarcinoma; LUSC, squamous cell carcinoma.

###### 

Correlation between IL-6 and IL-6R, IL-6R and IL-6ST.

               IL-6 vs. IL-6R   IL-6R vs. IL-6ST           
  ------------ ---------------- ------------------ ------- ---------------
  LUAD                                                     
    GSE14814   −0.345             **0.004**        0.141     0.245
    GSE30219   −0.515           **\<0.001**        0.506   **\<0.001**
    GSE37745   −0.107             0.272            0.294     **0.002**
    GSE42127     0.041            0.642            0.243     **0.005**
    GSE50081   −0.207             **0.019**        0.363   **\<0.001**
    GSE68465   −0.166             **0.001**        0.271   **\<0.001**
    GSE68571   −0.194             0.073            0.191     0.079
    TCGA       −0.165           **\<0.001**        0.527   **\<0.001**
    Pooled r   −0.199           **\<0.001**        0.331   **\<0.001**
  LUSC                                                     
    GSE14814     0.395            **0.004**        0.073     0.606
    GSE30219     0.036            0.782            0.469     **0.000**
    GSE37745     0.417            **0.001**        0.369     **0.002**
    GSE42127     0.610          **\<0.001**        0.272     0.077
    GSE50081     0.069            0.661            0.155     0.320
    TCGA         0.178          **\<0.001**        0.465     **\<0.001**
    Pooled r     0.288            **0.001**        0.334   **\<0.001**

P\<0.05 indicated in bold. Correlations were calculated using Pearson correlation coefficient and pooled correlations were performed using a meta-analysis based on Fisher\'s z transformation. IL, interleukin; TCGA, The Cancer Genome Atlas; LUAD, adenocarcinoma; LUSC, squamous cell carcinoma.

###### 

Top 5 biological processes and pathway of interleukin-6R and associated genes in lung adenocarcinoma.

  Analysis               ID           Biological processes                      P-value         Genes
  ---------------------- ------------ ----------------------------------------- --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biological processes   GO:0051301   Cell division                             4.038×10^−20^   CDK1, CDC6, PSRC1, TPX2, BIRC5, PTTG1, UBE2C, CDC25C, CDC25A, CCNB1, FAM83D, SPC25, NCAPH, CCNB2, CCND3, ZWINT, CDCA2, CKS2, SKA3, SKA1, CDCA5, ASPM, CDCA3
                         GO:0007067   Mitotic nuclear division                  3.084×10^−14^   CENPN, CDK1, NUF2, PTTG1, CDC25C, CDC25A, FAM83D, SPC25, CCNB2, PLK1, ZWINT, CDCA2, SKA3, CENPW, SKA1, ASPM
                         GO:0007059   Chromosome segregation                    1.529×10^−09^   SPC25, CENPN, KIF11, OIP5, NEK2, HJURP, SKA3, CENPW, BIRC5, SKA1
                         GO:0000070   Mitotic sister chromatid segregation      1.186×10^−06^   CDCA8, PLK1, NEK2, SPAG5, KIF18B, ESPL1
                         GO:0045143   Homologous chromosome                     5.275×10^−06^   PLK1, ESPL1, PTTG1
  Pathway                bta04110     Cell cycle                                8.584×10^−15^   CDK1, CDC6, TTK, CDC20, ESPL1, CHEK1, PTTG1, CDC25C, CDC25A, CCNB1, CDC45, CCNB2, MAD2L1, CCND3, PLK1, BUB1, BUB1B
                         bta04114     Oocyte meiosis                            2.573×10^−07^   CDK1, MAD2L1, LADCY9, PLK1, BUB1, FBXO5, ESPL1, CDC20, PTTG1, CDC25C
                         bta04914     Progesterone-mediated oocyte maturation   3.845×10^−06^   CCNB1, CDK1, MAD2L1, CCNB2, LADCY9, PLK1, BUB1, CDC25C, CDC25A
                         bta04115     p53 signaling pathway                     \<0.001         CCNB1, CDK1, CCNB2, CCND3, RRM2, CHEK1, GTSE1
                         bta05166     HTLV-I infection                          0.008           MAD2L1, CCND3, POLE2, LADCY9, BUB1B, CDC20, CHEK1, PTTG1

###### 

Top 5 biological processes and pathway of interleukin-6R and associated genes in lung squamous cell carcinoma.

  Analysis               ID           Biological processes                                                P-value   Genes
  ---------------------- ------------ ------------------------------------------------------------------- --------- -----------------------------------------------
  Biological processes   GO:0042127   Regulation of cell proliferation                                    0.001     TNFRSF1A, TNFRSF1B, FGR, PTK2B, JUNB, BTK
                         GO:0045672   Positive regulation of osteoclast differentiation                   0.003     FOS, KLF10, CCR1
                         GO:0006955   Immune response                                                     0.003     TNFRSF1A, TNFRSF1B, CCR1, CD4, CTSH, LCP2
                         GO:0007169   Trans-membrane receptor protein tyrosine kinase signaling pathway   0.006     DOK2, FGR, LCP2, BTK
                         GO:0007229   Integrin-mediated signaling pathway                                 0.006     ITGAL, FGR, PTK2B, TYROBP
  Pathway                ptr04650     Natural killer cell mediated cytotoxicity                           \<0.001   PTPN6, ITGAL, PTK2B, PRKCB, LCP2, TYROBP
                         ptr04380     Osteoclast differentiation                                          0.002     FOS, TNFRSF1A, JUNB, LCP2, BTK, TYROBP
                         ptr04611     Platelet activation                                                 0.011     VWF, LADCY9, PPP1CC, LCP2, BTK
                         ptr04060     Cytokine-cytokine receptor interaction                              0.015     TNFRSF1A, TNFRSF1B, IL2RB, CCR1, CXCL16, IL6R
                         ptr05166     HTLV-I infection                                                    0.028     FOS, ITGAL, TNFRSF1A, IL2RB, LADCY9, BUB1B

[^1]: Contributed equally
